| Literature DB >> 33353950 |
Kali R Iyer1, Kaddy Camara2,3, Martin Daniel-Ivad4, Richard Trilles2, Sheila M Pimentel-Elardo4, Jen L Fossen5,6, Karen Marchillo5,6, Zhongle Liu1, Shakti Singh7, José F Muñoz8, Sang Hu Kim1, John A Porco2, Christina A Cuomo8, Noelle S Williams9, Ashraf S Ibrahim7,10, John E Edwards7,10, David R Andes5,6, Justin R Nodwell4, Lauren E Brown2, Luke Whitesell1, Nicole Robbins1, Leah E Cowen11.
Abstract
Candida auris is an emerging fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed antifungal, fluconazole. Here, we use a combinatorial screening approach to identify a bis-benzodioxolylindolinone (azoffluxin) that synergizes with fluconazole against C. auris. Azoffluxin enhances fluconazole activity through the inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is conserved across most C. auris clades, with the exception of clade III. Azoffluxin also inhibits efflux in highly azole-resistant strains of Candida albicans, another human fungal pathogen, increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole activity in mice infected with C. auris, reducing fungal burden. Our findings suggest that pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to control infection caused by azole-resistant isolates of C. auris.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33353950 PMCID： PMC7755909 DOI： 10.1038/s41467-020-20183-3
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919